Prognostic Score predicting overall survival of Patients with Intermediate Stage of Hepatocellular Carcinoma after Transarterial Chemoembolization

被引：0
|
作者：
Jarupongprapa, Saharat [1 ]
Nimanong, Supot [1 ]
Chainuvati, Siwaporn [1 ]
Charatcharoenwitthaya, Phunchai [1 ]
Tanwandee, Tawesak [1 ]
Chotiyaputta, Watcharasak [1 ]
机构：
[1] Mahidol Univ, Siriraj Hosp, Internal Med, Gastroenterol, Bangkok 10700, Thailand
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
467
引用
收藏
页码：444A / 445A
页数：2
相关论文
共 50 条
  • [31] How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma
    Hucke, Florian
    Pinter, Matthias
    Graziadei, Ivo
    Bota, Simona
    Vogel, Wolfgang
    Mueller, Christian
    Heinzl, Harald
    Waneck, Fredrik
    Trauner, Michael
    Peck-Radosavljevic, Markus
    Sieghart, Wolfgang
    JOURNAL OF HEPATOLOGY, 2014, 61 (06) : 1287 - 1296
  • [32] New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization
    Kim, Jin Hyoung
    Shim, Ju Hyun
    Lee, Han Chu
    Sung, Kyu-Bo
    Ko, Heung-Kyu
    Ko, Gi-young
    Gwon, Dong Il
    Kim, Jong Woo
    Lim, Yung-Suk
    Park, Seong Ho
    LIVER INTERNATIONAL, 2017, 37 (12) : 1861 - 1868
  • [33] Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma
    Ni, Jia-Yan
    Sun, Hong-Liang
    Chen, Yao-Ting
    Luo, Jiang-Hong
    Chen, Dong
    Jiang, Xiong-Ying
    Xu, Lin-Feng
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (46) : 17483 - 17490
  • [34] Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma
    Jia-Yan Ni
    Hong-Liang Sun
    Yao-Ting Chen
    Jiang-Hong Luo
    Dong Chen
    Xiong-Ying Jiang
    Lin-Feng Xu
    World Journal of Gastroenterology, 2014, (46) : 17483 - 17490
  • [35] Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
    Roth, Gael Stephane
    Teyssier, Yann
    Abousalihac, Melodie
    Seigneurin, Arnaud
    Ghelfi, Julien
    Sengel, Christian
    Decaens, Thomas
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (03) : 324 - 334
  • [36] Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
    Ga?l Stéphane Roth
    Yann Teyssier
    Mélodie Abousalihac
    Arnaud Seigneurin
    Julien Ghelfi
    Christian Sengel
    Thomas Decaens
    World Journal of Gastroenterology, 2020, (03) : 324 - 334
  • [37] Time to untreatable progression is an appropriate surrogate endpoint for overall survival in patients with hepatocellular carcinoma after transarterial chemoembolization
    Wang, Hongyu
    Li, Bin
    Wang, Yu
    Zhang, Jiang
    Wu, Yanqin
    Fan, Wenzhe
    Li, Jiaping
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020, 16 (02) : 301 - 308
  • [38] Comparison of Survival of Patients with BCLC Stage A Hepatocellular Carcinoma After Hepatic Resection or Transarterial Chemoembolization: A Propensity Score-Based Analysis
    Zhe Guo
    Jian-Hong Zhong
    Jing-Hang Jiang
    Jun Zhang
    Bang-De Xiang
    Le-Qun Li
    Annals of Surgical Oncology, 2014, 21 : 3069 - 3076
  • [39] Comparison of Survival of Patients with BCLC Stage A Hepatocellular Carcinoma After Hepatic Resection or Transarterial Chemoembolization: A Propensity Score-Based Analysis
    Guo, Zhe
    Zhong, Jian-Hong
    Jiang, Jing-Hang
    Zhang, Jun
    Xiang, Bang-De
    Li, Le-Qun
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (09) : 3069 - 3076
  • [40] Risk Prognostic Factors With Transarterial Chemoembolization for Patients of Medium-stage Hepatocellular Carcinoma
    Yen, Chieh-Ling
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (07) : E119 - E120
12345